StreetInsider.com News Articles

Form 4 Evommune, Inc. For: Sep 30 Filed by: Pena Luis C.

Thu, 15 Oct 2026 16:29:00 -0400

si-local-file:///var/storage/secattach/20261015/27193738.html

UBS Starts Evommune Inc (EVMN) at Neutral

Mon, 12 Oct 2026 02:20:14 -0400

UBS analyst Alice Nettleton initiates coverage on Evommune Inc (NYSE: EVMN) with a Neutral rating and a price target of $8.00.

The analyst comments: “We initiate coverage of Evommune (EVMN) with a Neutral rating and $8 PT. Following positive Phase 2a data, we view EVO301 (IL-18 binding protein) as a credible emerging 2L option in atopic dermatitis (AD), with potential upside from additional indications. We model $330M in risk-adjusted 2035 AD sales, vs cons. at $600M. While EVO756 (MRGPRX2, "X2") recently failed in chronic spontaneous urticaria (CSU) and AD, we believe migraine represents an attractive commercial opportunity and are encouraged by

UBS Starts Evommune Inc (EVMN) at Neutral

Mon, 12 Oct 2026 02:20:14 -0400

UBS analyst Alice Nettleton initiates coverage on Evommune Inc (NYSE: EVMN) with a Neutral rating and a price target of $8.00.

Form 8-K Evommune, Inc. For: Oct 01

Thu, 01 Oct 2026 08:02:00 -0400

si-local-file:///var/storage/secattach/20261001/27131902.html

Evommune reports Phase 2a data for EVO301 in atopic dermatitis

Thu, 01 Oct 2026 08:01:33 -0400

Evommune, Inc. (NYSE: EVMN) presented late-breaking Phase 2a proof-of-concept data for its drug candidate EVO301 in adults with moderate-to-severe atopic dermatitis at the European Academy of Dermatology and Venereology Congress in Vienna, Austria.

The 70-patient trial evaluated intravenous dosing of 5mg/kg at baseline and Week 4, with 48 patients receiving the active drug and 22 receiving placebo. The primary endpoint was assessed at Week 12, eight weeks after the last dose.

EVO301 met the trial's primary endpoint, achieving a 55% least-squares mean reduction in the Eczema Area and Severity Index (EASI) from baseline at Week 12, compared with 22% on placebo (p<0.01).

Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology Congress

Thu, 01 Oct 2026 08:00:00 -0400

Presentation highlights EVO301’s clear therapeutic signal, favorable safety and tolerability profile, and reinforces IL-18 inhibition as a novel, clinically relevant approach to treating atopic dermatitis
Biomarker analyses confirm robust Th2 pathway modulation, as well as broad anti-inflammatory activity across multiple inflammatory pathways (Th1, Th17/22)
Plan to initiate subcutaneous Phase 2b dose-ranging trial in mid-2027

PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--

Evommune, Inc. (NYSE: EVMN) (the “Company” or “Evommune”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today shared additional data from its Phase 2a proof-of-concept trial of

Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology Congress

Thu, 01 Oct 2026 08:00:00 -0400

Presentation highlights EVO301’s clear therapeutic signal, favorable safety and tolerability profile, and reinforces IL-18 inhibition as a novel, clinically relevant approach to treating atopic dermatitis
Biomarker analyses confirm robust Th2 pathway modulation, as well as broad anti-inflammatory activity across multiple inflammatory pathways (Th1, Th17/22)
Plan to initiate subcutaneous Phase 2b dose-ranging trial in mid-2027

PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--

Evommune to present EVO301 phase 2a data at EADV congress

Wed, 23 Sep 2026 16:05:30 -0400

Evommune, Inc. (NYSE: EVMN) announced that Phase 2a trial data for its drug candidate EVO301 in moderate-to-severe atopic dermatitis will be presented in a late-breaking oral session at the European Academy of Dermatology and Venereology (EADV) Congress in Vienna, Austria, running from September 30 to October 3, 2026.

The presentation is scheduled for October 1 at 4:30 p.m. CEST in Hall A. Dr. Mark G. Lebwohl, Dean for Clinical Therapeutics and Chairman Emeritus of the Department of Dermatology at Icahn School of Medicine at Mount Sinai, will present the data.

EVO301 is a long-acting injectable fusion protein designed to neutralize IL-18, an

Form 8-K Evommune, Inc. For: Sep 23

Wed, 23 Sep 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260923/27096764.html

Evommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 Congress

Wed, 23 Sep 2026 16:05:00 -0400

PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)-- Evommune, Inc. (NYSE: EVMN) (“Evommune” or the “Company”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced that data from the Phase 2a trial of EVO301 in moderate-to-severe atopic dermatitis (AD) will be presented in a late-breaking oral session at the upcoming European Academy of Dermatology & Venereology (EADV) Congress, taking place in Vienna, Austria from September 30 to October 3, 2026.

EVO301 is a long-acting, native IL-18 binding protein (IL-18BP) fused to a serum albumin binding Fab, designed

Evommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 Congress

Wed, 23 Sep 2026 16:05:00 -0400

EVO301 is a long-acting, native IL-18 binding protein (IL-18BP) fused to a serum albumin binding Fab, designed

Evommune (EVMN) Reiterated at Overweight by Cantor Fitzgerald on Tweaked OPEX Estimates

Fri, 18 Sep 2026 07:03:21 -0400

Cantor Fitzgerald analyst Prakhar Agrawal reiterated an Overweight rating on Evommune Inc (NYSE: EVMN).

The analyst commented, "We tweaked our OPEX estimates following recent corporate updates, which increased our EPS loss estimates for 2026 and 2027. No change to our OW rating."

For an analyst ratings summary and ratings history on Evommune Inc click here. For more ratings news on Evommune Inc click here.

Shares of Evommune Inc closed at $9.37 yesterday.

Form 8-K Evommune, Inc. For: Sep 15

Tue, 15 Sep 2026 08:31:00 -0400

si-local-file:///var/storage/secattach/20260915/27061738.html

Stifel Reiterates Buy Rating on Evommune Inc (EVMN)

Wed, 09 Sep 2026 09:37:24 -0400

Stifel analyst Alex Thompson reiterated a Buy rating and $30.00 price target on Evommune Inc (NYSE: EVMN).

The analyst commented, "EVMN reported a clear Ph2b miss for EVO756 (MRGPRX2) in AD (N=121). We caught up with management who characterized placebo as modestly elevated and safety similar to CSU with transient, reversible AST/ALT elevations at the top doses without bilirubin/ALP elevations. There was one elevation at the mid-dose that declined on treatment and was considered unlikely drug related. The Ph2b migraine study uses mid/low doses and is on track for 2027. This represents another setback for X2 following June's CSU miss as

Evommune Inc (EVMN) PT Lowered to $21 at RBC Capital

Wed, 09 Sep 2026 07:55:04 -0400

(Updated - September 9, 2026 7:55 AM EDT)

RBC Capital analyst Brian Abrahams lowered the price target on Evommune Inc (NYSE: EVMN) to $21.00 (from $29.00) while maintaining an Outperform rating.

The analyst commented: '756 Falters Again, This Time in AD, But Third Time (Migraine) Could Be Charm, And IL-18 Has Value; Failure of '756 in AD is disappointing, though after the lack of signals in the CSU data, we believe expectations were low going in, and we had assumed a relatively niche potential opportunity for the drug upon success. Results continue to call into some question the drug's profile and X2

Evommune Inc (EVMN) PT Lowered to $21 at RBC Capital

Wed, 09 Sep 2026 07:55:04 -0400

(Updated - September 9, 2026 7:55 AM EDT)

RBC Capital analyst Brian Abrahams lowered the price target on Evommune Inc (NYSE: EVMN) to $21.00 (from $29.00) while maintaining an Outperform rating.

Clear Street Reiterates Buy Rating on Evommune Inc (EVMN) Amid 15% Drop

Wed, 09 Sep 2026 06:58:24 -0400

Clear Street analyst Kaveri Pohlman reiterated a Buy rating and $28.00 price target on Evommune Inc (NYSE: EVMN).

The analyst comments "EVMN shares fell after P2b EVO756 in AD failed to meet primary or secondary endpoints at any dose through week-14. While disappointing given translational data supporting MRGPRX2 in AD, we believe the migraine program retains an independent shot on goal, reinforced by Lundbeck’s (Nasdaq Copenhagen: HLUN-B, NC) positive anti-PACAP ligand mAb data, providing strong readthrough to EVO756. P2b AD safety matched prior CSU experience: AST/ALT elevations occurred in a few patients (weeks 6–10) at the highest dose and were reversible.

Clear Street Reiterates Buy Rating on Evommune Inc (EVMN) Amid 15% Drop

Wed, 09 Sep 2026 06:58:24 -0400

Clear Street analyst Kaveri Pohlman reiterated a Buy rating and $28.00 price target on Evommune Inc (NYSE: EVMN).

Form 424B3 Evommune, Inc.

Wed, 09 Sep 2026 06:01:00 -0400

si-local-file:///var/storage/secattach/20260909/27038567.html

Form 8-K Evommune, Inc. For: Sep 08

Wed, 09 Sep 2026 06:01:00 -0400

si-local-file:///var/storage/secattach/20260909/27038550.html

Evommune's EVO756 fails atopic dermatitis trial endpoints

Tue, 08 Sep 2026 17:43:19 -0400

Evommune, Inc. (NYSE: EVMN) announced that its Phase 2b clinical trial of EVO756 in adults with moderate-to-severe atopic dermatitis did not meet its primary or secondary endpoints at any dose studied.

The randomized, double-blind, placebo-controlled trial enrolled 121 adults over a 12-week treatment period, with follow-up through Week 14. The primary endpoint was percent change in Eczema Area and Severity Index score from baseline at Week 12. The company said it does not plan to advance EVO756 in atopic dermatitis.

EVO756 was described as generally well tolerated, with a safety profile consistent with prior studies. Evommune said it plans to continue Phase

Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Atopic Dermatitis

Tue, 08 Sep 2026 17:43:00 -0400

- Trial did not meet the primary endpoint of percent change in Eczema Area and Severity Index (EASI) score from baseline at Week 12; EVO756 was generally well tolerated

- EVO301, the Company’s IL-18BP fusion protein, advances as lead atopic dermatitis program following positive Phase 2a proof-of-concept data

- Evommune to continue Phase 2b development of EVO756 in migraine prophylaxis

PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)-- Evommune, Inc. (NYSE: EVMN) (the “Company” or “Evommune”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced top-line results from its randomized,

Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Atopic Dermatitis

Tue, 08 Sep 2026 17:43:00 -0400

- Trial did not meet the primary endpoint of percent change in Eczema Area and Severity Index (EASI) score from baseline at Week 12; EVO756 was generally well tolerated

- EVO301, the Company’s IL-18BP fusion protein, advances as lead atopic dermatitis program following positive Phase 2a proof-of-concept data

- Evommune to continue Phase 2b development of EVO756 in migraine prophylaxis

Needham Starts Evommune Inc (EVMN) at Buy

Wed, 26 Aug 2026 06:20:24 -0400

Needham analyst Serge Belanger initiates coverage on Evommune Inc (NYSE: EVMN) with a Buy rating and a price target of $28.00.

For an analyst ratings summary and ratings history on Evommune Inc click here. For more ratings news on Evommune Inc click here.

Shares of Evommune Inc closed at $13.79 yesterday.

Form SCHEDULE 13G/A Evommune, Inc. Filed by: Andera Partners

Fri, 14 Aug 2026 16:27:00 -0400

si-local-file:///var/storage/secattach/20260814/26931186.html